Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH82277FSA
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Orexo AB (ORX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company's operations and business divisions.

- Corporate strategy - Analyst's summarization of the company's business strategy.

- SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history - Progression of key events associated with the company.

- Major products and services - A list of major products, services and brands of the company.

- Key competitors - A list of key competitors to the company.

- Key employees - A list of the key executives of the company.

- Executive biographies - A brief summary of the executives' employment history.

- Key operational heads - A list of personnel heading key departments/functions.

- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities - A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexo AB (Orexo) is a specialty pharmaceutical company that focuses on the research, formulation, development, registration and commercialization of drugs. The company's commercial product portfolio consists of Abstral, Edluar and Zubsolv. its pipeline candidates comprise OX51 for procedure-induced pain; OX-CLI for respiratory tract diseases; and OX-MPI for inflammation. The company employs its proprietary drug delivery technologies in the development of these products. It also carries out the industrial-scale production of pharmaceutical products. Orexo works in collaboration with various pharmaceutical companies including, Meda, Kyowa Hakko Kirin, Sentynl Therapeutics, ProStrakan, AstraZeneca and Mundipharma to advance and commercialize its products. Orexo is headquartered in Uppsala, Sweden.

Orexo AB Key Recent Developments

Jul 11,2018: Orexo: Interim Report Q2 2018

May 31,2018: Orexo's CFO resigns and will leave the company in November 2018

Apr 26,2018: Orexo - Interim Report Q1 2018

Feb 06,2018: Orexo participating in new project concerning R&D for Drug Delivery technologies in collaboration with Uppsala University

Jan 25,2018: Orexo: Full Year Report Q4 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Orexo AB - Key Facts 6

Orexo AB - Key Employees 7

Orexo AB - Key Employee Biographies 8

Orexo AB - Major Products and Services 9

Orexo AB - History 10

Orexo AB - Company Statement 14

Orexo AB - Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2 - Company Analysis 16

Company Overview 16

Orexo AB - Business Description 17

Product Category: Abstral 17

Overview 17

Performance 17

Product Category: Edluar 17

Overview 17

Performance 17

Product Category: Zubsolv 17

Overview 17

Performance 18

Product Category: Milestone 18

Performance 18

Geographical Segment: East Asia 18

Performance 18

Geographical Segment: Sweden 18

Performance 18

Geographical Segment: The UK 18

Performance 18

Geographical Segment: The US 18

Performance 18

R&D Overview 18

Orexo AB - SWOT Analysis 19

SWOT Analysis - Overview 19

Orexo AB - Strengths 19

Orexo AB - Weaknesses 20

Orexo AB - Opportunities 21

Orexo AB - Threats 22

Orexo AB - Key Competitors 23

Section 3 - Company Financial Ratios 24

Financial Ratios - Capital Market Ratios 24

Financial Ratios - Annual Ratios 25

Performance Chart 28

Financial Performance 28

Financial Ratios - Interim Ratios 29

Financial Ratios - Ratio Charts 30

Section 4 - Company's Lifesciences Financial Deals and Alliances 31

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Orexo AB, Recent Deals Summary 33

Section 5 - Company's Recent Developments 34

Jul 11, 2018: Orexo: Interim Report Q2 2018 34

May 31, 2018: Orexo's CFO resigns and will leave the company in November 2018 35

Apr 26, 2018: Orexo - Interim Report Q1 2018 36

Feb 06, 2018: Orexo participating in new project concerning R&D for Drug Delivery technologies in collaboration with Uppsala University 37

Jan 25, 2018: Orexo: Full Year Report Q4 2017 38

Oct 19, 2017: Orexo Interim Report Q3 2017 39

Sep 05, 2017: Orexo, together with Malmo University, receives research grant 40

Jul 11, 2017: Orexo Interim Report Q2 2017 41

Apr 20, 2017: Orexo: Interim Report Q1 2017 47

Jan 26, 2017: Orexo: Full Year Report 2016 48

Section 6 - Appendix 49

Methodology 49

Ratio Definitions 49

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

Orexo AB, Performance Chart (2013 - 2017) 28

Orexo AB, Ratio Charts 30

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Orexo AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

List of Tables

Orexo AB, Key Facts 6

Orexo AB, Key Employees 7

Orexo AB, Key Employee Biographies 8

Orexo AB, Major Products and Services 9

Orexo AB, History 10

Orexo AB, Subsidiaries 15

Orexo AB, Key Competitors 23

Orexo AB, Ratios based on current share price 24

Orexo AB, Annual Ratios 25

Orexo AB, Annual Ratios (Cont...1) 26

Orexo AB, Annual Ratios (Cont...2) 27

Orexo AB, Interim Ratios 29

Orexo AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Orexo AB, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Orexo AB, Recent Deals Summary 33

Currency Codes 49

Capital Market Ratios 49

Equity Ratios 50

Profitability Ratios 50

Cost Ratios 51

Liquidity Ratios 51

Leverage Ratios 52

Efficiency Ratios 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

SpectraCure AB

Palau Pharma SA

NeuroVive Pharmaceutical AB

Karo Pharma AB

Indivior Plc

Fastilium Property Group AB

Orexo AB, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8920
Site License
USD 250 INR 17840
Corporate User License
USD 375 INR 26760

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com